Cited by 337Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.

From mice to humans: developments in cancer immunoediting

Open access

Teng, Michele W.L., Galon, Jerome, Fridman, Wolf-Herman, Smyth, Mark J.·2015·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8+ T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci80004

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Given the heterogeneity of tumors (61), it would be wise to vaccinate with a number of TSMAs, if possible, to reduce the emergence of escape variants.”
Background
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Show all 123 references

Sorted by citations

Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826
Self-citation
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,382
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,342
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citation
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 456
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 438
Self-citation
Hypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397
Current status and future directions of cancer immunotherapy
Zhang, H., & Chen, J. (2018) · Journal of Cancer · doi:10.7150/jca.24577 · Cited by 366
The concept of immune surveillance against tumors: The first theories
Ribatti, D. (2016) · Oncotarget · doi:10.18632/oncotarget.12739 · Cited by 361
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
Xu, X., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 329
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Jafari, S. M. S., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 315
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., Hermann‐Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02424-0 · Cited by 308
Aging and cancer: The role of macrophages and neutrophils
Jackaman, C., Tomay, F., Duong, L., Abdol Razak, N. B., Pixley, F. J., Metharom, P., & Nelson, D. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.008 · Cited by 251
The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 254
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 242
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 232
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 220
Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers
Becht, É., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent‐Puig, P., Zucman‐Rossi, J., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 224
Self-citation
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 214
The Interferon-Gamma Paradox in Cancer
Zaidi, M. R. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0087 · Cited by 196
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Xu, Y., Xiong, J., Sun, X., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.001 · Cited by 188
Occupational and environmental exposure to pesticides and cytokine pathways in chronic diseases (Review)
Gangemi, S., Gofiţă, E., Costa, C., Teodoro, M., Briguglio, G., Nikitovic, D., Tzanakakis, G. N., Tsatsakis, A. M., Wilks, M. F., Spandidos, D. A., et al. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2728 · Cited by 181
CXCL9: evidence and contradictions for its role in tumor progression
Ding, Q., Lu, P., Xia, Y., Ding, S., Fan, Y., Li, X., Han, P., Liu, J., Tian, D., & Liu, M. (2016) · Cancer Medicine · doi:10.1002/cam4.934 · Cited by 164
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Wu, L., Wei, Q., Brzostek, J., & Gascoigne, N. R. J. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0470-3 · Cited by 164
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Kotsafti, A., Scarpa, M., Castagliuolo, I., & Scarpa, M. (2020) · Cancers · doi:10.3390/cancers12071748 · Cited by 161
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 161
Immune Checkpoint Inhibitors in Human Glioma Microenvironment
Ghouzlani, A., Kandoussi, S., Tall, M., Reddy, K. P., Rafii, S., & Badou, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679425 · Cited by 142
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 142
Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses
Morrot, A., da Fonseca, L. M., Salustiano, E. J., Gentile, L. B., Conde, L., Filardy, A. A., Franklim, T. N., da Costa, K. M., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00081 · Cited by 128
Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization
Thyagarajan‐Sahu, A., & Sahu, R. P. (2017) · Integrative Cancer Therapies · doi:10.1177/1534735416681639 · Cited by 126
Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma
Li, T., Li, K., Zhang, Q., Wang, C., Yue, Y., Chen, Z., Yuan, S.-J., Liu, X., Wen, Y., Han, M. H., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.035 · Cited by 126
Long noncoding RNAs in cancer‐immunity cycle
Yu, W., Wang, H., He, Q., Xu, Y., & Wang, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26568 · Cited by 124
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 125
Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine
Bashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 128
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Inflammation and Cancer
Ribatti, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-68448-2_5 · Cited by 115
Tertiary Lymphoid Organs in Cancer Tissues
Hiraoka, N., Ino, Y., & Yamazaki–Itoh, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00244 · Cited by 109
Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions
Yagyuu, T., Hatakeyama, K., Imada, M., Kurihara, M., Matsusue, Y., Yamamoto, K., Obayashi, C., & Kirita, T. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.03.006 · Cited by 104
Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
Mello, P. D. A., Coutinho‐Silva, R., & Savio, L. E. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01526 · Cited by 108
Characterization of immune cell populations in the tumor microenvironment of colorectal cancer using high definition spatial profiling
Oliveira, M. F., Romero, J. P., Chung, M., Williams, S., Gottscho, A. D., Gupta, A., Pilipauskas, S. E., Mohabbat, S., Raman, N., Sukovich, D., et al. (2024) · doi:10.1101/2024.06.04.597233 · Cited by 95
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Tan, D. S. W., Felip, E., de Castro, G., Solomon, B., Greystoke, A., Cho, B. C., Cobo, M., Kim, T. M., Ganguly, S., Carcereny, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00980 · Cited by 97
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 100
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernández, G., García-Granda, M. J., Blanco, E., Vera, R., Kochan, G. T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 94
A novel inflammation-related lncRNAs prognostic signature identifies LINC00346 in promoting proliferation, migration, and immune infiltration of glioma
Zeng, W., Zhang, L., Cao, H., Li, D., Zhang, H., Xia, Z., & Peng, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810572 · Cited by 92
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk
Piening, A., Ebert, E. C., Gottlieb, C., Khojandi, N., Kuehm, L. M., Hoft, S. G., Pyles, K. D., McCommis, K. S., DiPaolo, R. J., Ferris, S. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47359-5 · Cited by 95
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Shen, L., Zhou, Y., He, H., Chen, W., Lenahan, C., Li, X., Deng, Y., Shao, A., & Huang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8865791 · Cited by 92
Breast Cancer Vaccines: Disappointing or Promising?
Zhu, S., & Yu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828386 · Cited by 96
TH9 cells in anti-tumor immunity
Vargas, T. R., Humblin, É., Végran, F., Ghiringhelli, F., & Apétoh, L. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0599-4 · Cited by 88
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Šmahel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061331 · Cited by 84
Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma
Boxberg, M., Leising, L., Steiger, K., Jesinghaus, M., Alkhamas, A., Mielke, M., Pfarr, N., Götz, C., Wolff, K. D., Weichert, W., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800242 · Cited by 79
Colorectal cancer prevention: Immune modulation taking the stage
Fletcher, R., Wang, Y., Schoen, R. E., Finn, O. J., Yu, J., & Zhang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.002 · Cited by 82
New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine
Xu, H., Lin, S., Zhou, Z., Li, D., Zhang, X., Yu, M., Zhao, R., Wang, Y., Qian, J., Li, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01032-x · Cited by 78
Role of CXC group chemokines in lung cancer development and progression
Špaks, A. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.61 · Cited by 71
Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework
Haas, O. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03136 · Cited by 70
Advances in the interaction of glycolytic reprogramming with lactylation
Li, Y., Cao, Q., Hu, Y., He, B., Cao, T., Tang, Y., Zhou, X. P., Lan, X. P., & Liu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116982 · Cited by 71
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 73
The Immunoregulatory Potential of Particle Radiation in Cancer Therapy
Ebner, D. K., Tinganelli, W., Helm, A., Bisio, A., Yamada, S., Kamada, T., Shimokawa, T., & Durante, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00099 · Cited by 66
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
Yu, Y.-R., & Ho, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13293 · Cited by 66
Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development
Degnim, A. C., Hoskin, T. L., Arshad, M., Frost, M. H., Winham, S. J., Brahmbhatt, R. A., Peña, A., Carter, J. M., Stallings‐Mann, M. L., Murphy, L. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2026 · Cited by 65
The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63
Leveraging premalignant biology for immune-based cancer prevention
Spira, A. E., Disis, M. L., Schiller, J. T., Vilar, E., Rebbeck, T. R., Bejar, R. L., Ideker, T., Arts, J., Yurgelun, M. B. B., Mesirov, J. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608077113 · Cited by 64
Electroporation and Immunotherapy—Unleashing the Abscopal Effect
Justesen, T. F., Orhan, A., Raskov, H., Nolsøe, C., & Gögenür, I. (2022) · Cancers · doi:10.3390/cancers14122876 · Cited by 67
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 66
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 62
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy
Haworth, K. B., Arnold, M., Pierson, C. R., Choi, K., Yeager, N. D., Ratner, N., Roberts, R. D., Finlay, J. L., & Cripe, T. P. (2017) · Oncotarget · doi:10.18632/oncotarget.18301 · Cited by 61
Chaperone-assisted E3 ligase CHIP: A double agent in cancer
Kumar, S., Basu, M., & Ghosh, M. K. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.003 · Cited by 59
Novel therapeutic strategies for spinal osteosarcomas
Anwar, M. A., El‐Baba, C., Elnaggar, M. H., Elkholy, Y. O., Mottawea, M., Johar, D., Shehabi, T. S. A., Kobeissy, F. H., Moussalem, C. K., Massaad, E., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.018 · Cited by 58
Who is who in oral cancer?
Zhang, W., Wang, S., Wang, H., Tang, Y.-J., Tang, Y., & Liang, X. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111634 · Cited by 57
Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment
Zheng, D., Wan, C., Yang, H., Xu, L., Dong, Q., Du, C., Du, J., & Li, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s271213 · Cited by 56
P2 receptors in cancer progression and metastatic spreading
Virgilio, F. D., Falzoni, S., Giuliani, A. L., & Adinolfi, E. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.05.001 · Cited by 56
Extracellular vesicles in lung cancer—From bench to bedside
Kadota, T., Yoshioka, Y., Fujita, Y., Kuwano, K., & Ochiya, T. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.03.001 · Cited by 55
The Janus Face of Death Receptor Signaling during Tumor Immunoediting
Reilly, E. O., Tirincsi, A., Logue, S. E., & Szegezdi, É. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00446 · Cited by 51
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese, T., Tamma, R., & Ribatti, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871085 · Cited by 54
Altered CD8+ T-Cell Lymphocyte Function and TC1 Cell Stemness Contribute to Enhanced Malignant Tumor Properties in Murine Models of Sleep Apnea
Akbarpour, M., Khalyfa, A., Qiao, Z., Gileles‐Hillel, A., Almendros, I., Farré, R., & Gozal, D. (2016) · SLEEP · doi:10.1093/sleep/zsw040 · Cited by 49
Metabolism and Gut Microbiota in Cancer Immunoediting, CD8/Treg Ratios, Immune Cell Homeostasis, and Cancer (Immuno)Therapy: Concise Review
Kareva, I. (2019) · Stem Cells · doi:10.1002/stem.3051 · Cited by 50
Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis
Jin, M., Yuan, S., Yuan, Y., & Yi, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735803 · Cited by 50
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes
Yahiro, K., Matsumoto, Y., Yamada, H., Endo, M., Setsu, N., Fujiwara, T., Nakagawa, M., Kimura, A., Shimada, E., Okada, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02508-9 · Cited by 47
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez‐Romero, K., Rodríguez, R. M. A., Amedei, A., Barceló‐Coblijn, G., & Lopez, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 49
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli, M. L., Stover, D. G., Loi, S., Aparicio, S. A. J. R., Carey, L., Domchek, S. M., Newman, L. A., Sledge, G. W., & Winer, E. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4807-x · Cited by 43
Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
Jiménez‐Morales, S., Aranda-Uribe, I. S., Pérez-Amado, C. J., Ramírez‐Bello, J., & Hidalgo‐Miranda, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737340 · Cited by 47
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47
Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma
Zolkind, P., Przybylski, D., Marjanovic, N. D., Nguyễn, L., Lin, T., Johanns, T. M., Alexandrov, A., Zhou, L., Allen, C. T., Miceli, A. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23751 · Cited by 42
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4380 · Cited by 41
Cell Competition in Carcinogenesis
Madan, E., Palma, A. M., Vudatha, V., Trevino, J. G., Natarajan, K. N., Winn, R. A., Won, K., Graham, T. A., Drapkin, R., McDonald, S. A. C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2217 · Cited by 45
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39
Cancer immunoediting hypothesis: history, clinical implications and controversies
Lasek, W. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.117376 · Cited by 39
Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway
Andreuzzi, E., Fejza, A., Polano, M., Poletto, E., Camicia, L., Carobolante, G., Tarticchio, G., Todaro, F., Carlo, E. D., Scarpa, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02271-y · Cited by 37
Overview of Research and Development for Anticancer Drugs
Xu, J., & Mao, W. (2016) · Journal of Cancer Therapy · doi:10.4236/jct.2016.710077 · Cited by 34
Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes
Tu, Y., Johnstone, C. N., & Stewart, A. G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.011 · Cited by 34
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Tarantelli, C., Argnani, L., Zinzani, P. L., & Bertoni, F. (2021) · Cancers · doi:10.3390/cancers13215535 · Cited by 35

Authors: Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J.
Affiliations: The University of Queensland (AU)
Inserm (FR)
ORCID: Teng, Michele W.L.
Fridman, Wolf-Herman
Smyth, Mark J.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2015-08-04
Volume: 125
Issue: 9
Pages: 3338-3346
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci80004
PMC: PMC4588291
OpenAlex: W1923943509
Cited by: 337
References: 123
Citations by year: 2026: 11 · 2025: 15 · 2024: 29 · 2023: 33 · 2022: 45 · 2021: 42 · 2020: 40 · 2019: 26 · 2018: 27 · 2017: 41 · 2016: 26 · 2015: 2
FWCI: 3.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Prostate Cancer Foundation
Prostate Cancer Foundation of Australia
Medical Research Council
National Health and Medical Research Council (1013667, 1059862, 1078671, 1021139)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunoediting, tumor immune microenvironment, CD8+ T cells, adaptive immune resistance, metastasis, primary tumor, mouse tumor model, human cancer
MeSH terms: Animals, Humans, Neoplasms, CD8-Positive T-Lymphocytes, Mice, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

From mice to humans: developments in cancer immunoediting

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks